HAE240719C85000
- 2.30
- 0.000.00%
Haemonetics Newsroom
Haemonetics Analyst Ratings
Haemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial Optimism
Haemonetics Analyst Ratings
Barrington Research: Maintaining the Haemonetics (HAE.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $105.00 to $107.00.
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $107
Haemonetics Analyst Ratings
Needham: Reiterates that Haemonetics (HAE.US) holds the rating.
Haemonetics (HAE) Gets a Hold From Needham
Barrington Research: Maintaining the Haemonetics (HAE.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $105.00 to $105.00.
Haemonetics Analyst Ratings
Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
Needham Remains a Hold on Haemonetics (HAE)
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Biogen (BIIB) and Axsome Therapeutics (AXSM)
Haemonetics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Shattuck Labs (STTK)
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), ALX Oncology Holdings (ALXO)
Needham Sticks to Its Hold Rating for Haemonetics (HAE)
Haemonetics (HAE): Promising Growth in Plasma Segment and International Expansion Fuels Buy Rating Despite Short-Term Concerns
Haemonetics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Haemonetics (HAE) and CVRx (CVRX)